The ALVAC/AIDSVAX prime-boost combination HIV vaccine demonstrated a small and only marginally significant protective effect in the Phase III RV144 clinical trial in Thailand. While detailed data did not live up to the initial hype, some researchers hailed the findings as proof-of-concept that a preventive HIV vaccine can work.
In September, the U.S. Military HIV Research Program (MHRP) announced that in an analysis of more than 16,000 study participants, those who received ALVAC/AIDSVAX had a 31% lower risk of HIV infection compared with placebo recipients. However, a closer look at the complete data, presented at the AIDS Vaccine 2009 conference in Paris and simultaneously published in the October 20, 2009, online edition of the New England Journal of Medicine, revealed less impressive results.
Overall, 56 vaccine recipients and 76 placebo recipients were newly infected with HIV during follow-up. In an intent-to-treat analysis, there was a trend toward a significant protective effect, with an efficacy of 26.4%; however, the P value (a standard statistical measure) of 0.08 did not reach the usual 0.05 cut-off for significance and the confidence interval was very wide, indicating considerable uncertainty about whether the results were due to chance alone.
"Although the results show only a modest benefit, they offer insight for future research," the RV144 investigators concluded. For example, they plan to explore why ALVAC/AIDSVAX provided the greatest protective effect during the first year (about a 60% risk reduction), and why heterosexual participants at low or medium risk for HIV infection appeared to derive more benefit than high-risk participants such as gay men or injection drug users.
The Thai trial results were "the first signal of [HIV vaccine] efficacy, extremely modest though it might be," National Institute of Allergy and Infectious Diseases director Anthony Fauci said at a CROI plenary. In particular, the findings may offer insights about the correlates of protection, or what needs to happen for a vaccine to work.
Liz Highleyman (email@example.com) is a freelance medical writer based in San Francisco.
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|